Alkermes has settled a lawsuit with Teva Pharmaceuticals establishing patent protection for the opioid and alcohol dependence treatment Vivitrol (extended-release injectable suspension of ...

Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Alkermes derives revenues from the net sales of its proprietary products — Vivitrol (alcohol and opioid dependence), Aristada ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of ...

Multaq (dronedarone) is prescribed for certain adults to help prevent a hospital stay for atrial fibrillation (AFib). This oral tablet can interact with other medications and some supplements ...

Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the ...

Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the ...

Inventory in the channel decreased by approximately $2.3 million during the quarter. ARISTADA i Revenues for the quarter were $78.9 million. Inventory in the channel decreased by approximately $3.6 ...